Repligen Corp. (RGEN)
167.60
-2.01
(-1.19%)
USD |
NASDAQ |
Sep 04, 16:00
167.57
-0.03
(-0.02%)
After-Hours: 20:00
Repligen SG&A Expense (TTM) : 301.18M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 301.18M |
| March 31, 2026 | 295.79M |
| December 31, 2025 | 290.51M |
| September 30, 2025 | 276.62M |
| June 30, 2025 | 278.57M |
| March 31, 2025 | 272.82M |
| December 31, 2024 | 263.37M |
| September 30, 2024 | 260.52M |
| June 30, 2024 | 240.50M |
| March 31, 2024 | 224.10M |
| December 31, 2023 | 218.58M |
| September 30, 2023 | 214.19M |
| June 30, 2023 | 212.25M |
| March 31, 2023 | 217.82M |
| December 31, 2022 | 215.83M |
| September 30, 2022 | 214.65M |
| June 30, 2022 | 209.38M |
| March 31, 2022 | 199.07M |
| December 31, 2021 | 183.87M |
| September 30, 2021 | 168.15M |
| June 30, 2021 | 148.83M |
| March 31, 2021 | 131.22M |
| December 31, 2020 | 119.62M |
| September 30, 2020 | 111.56M |
| June 30, 2020 | 107.14M |
| Date | Value |
|---|---|
| March 31, 2020 | 104.12M |
| December 31, 2019 | 95.61M |
| September 30, 2019 | 85.30M |
| June 30, 2019 | 76.53M |
| March 31, 2019 | 69.42M |
| December 31, 2018 | 66.32M |
| September 30, 2018 | 64.49M |
| June 30, 2018 | 63.63M |
| March 31, 2018 | 58.23M |
| December 31, 2017 | 51.51M |
| September 30, 2017 | 43.93M |
| June 30, 2017 | 36.06M |
| March 31, 2017 | 33.02M |
| December 31, 2016 | 30.85M |
| September 30, 2016 | 28.76M |
| June 30, 2016 | 27.59M |
| March 31, 2016 | 25.69M |
| December 31, 2015 | 24.70M |
| September 30, 2015 | 23.20M |
| June 30, 2015 | 21.71M |
| March 31, 2015 | 19.80M |
| December 31, 2014 | 17.16M |
| September 30, 2014 | 15.55M |
| June 30, 2014 | 13.98M |
| March 31, 2014 | 12.78M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| BioLife Solutions, Inc. | 55.36M |
| Anika Therapeutics, Inc. | 52.67M |
| Danaher Corp. | 7.949B |
| Liquidia Corp. | 192.66M |
| Harmony Biosciences Holdings, Inc. | 272.47M |